Related Experiment Videos

Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity

O F Dos Santos1, M A Boim, E J Barros

  • 1Nephrology Division, Escola Paulista de Medicina, São Paulo, Brasil.

Kidney International
|October 1, 1991
PubMed

Insights

Platelet activating factor (PAF) antagonists partially protected against gentamicin nephrotoxicity and fully prevented cisplatin-induced acute renal failure in rats, suggesting PAF

Area of Science:

  • Nephrology
  • Pharmacology
  • Toxicology

Background:

  • Gentamicin (GENTA) and cisplatin (DDP) are nephrotoxic drugs.
  • Platelet activating factor (PAF) plays a role in renal injury.

Purpose of the Study:

  • To investigate the protective effects of PAF antagonists against GENTA and DDP-induced nephrotoxicity in rats.
  • To elucidate the role of PAF in drug-induced kidney injury.

Main Methods:

  • Rats were treated with GENTA or DDP to induce nephrotoxicity.
  • PAF antagonists (BN 52021 and BN 52063) were administered concurrently or chronically.
  • Single nephron glomerular filtration rate (SNGFR) and its determinants (glomerular plasma flow, hydraulic pressure, ultrafiltration coefficient) were measured.

Main Results:

  • GENTA induced a significant decline in SNGFR, glomerular plasma flow, and ultrafiltration coefficient.
  • DDP caused acute renal failure with reduced SNGFR and glomerular plasma flow.
  • PAF antagonists partially ameliorated GENTA nephrotoxicity and completely prevented DDP-induced acute renal failure.

Conclusions:

  • PAF is implicated as a mediator in gentamicin and cisplatin-induced nephrotoxicity.
  • PAF antagonists demonstrate potential therapeutic value in mitigating drug-induced kidney injury.

Related Concept Videos